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anglais
An obesity-related altered adipose tissue secretion is suggested as a risk factor for
hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) cirrhosis.
However, no prospective study has yet examined the predictive value of circulating
adipokines and immuno-inflammatory biomarkers regarding this risk. This was a case-
control study nested in a prospective French national cohort of HCV-infected patients
with biopsy-proven compensated cirrhosis. We selected 56 HCV1-infected patients
who subsequently developed HCC (cases), and 96 controls matched for age, gender
and diabetes, not developing HCC after a similar period. Adipokines and immuno-
inflammatory biomarkers were determined on baseline frozen serum samples. Their
influence on the occurrence of HCC was assessed using a mixed logistic regression
model under univariate analysis and a backward stepwise procedure under
multivariate analysis. The patients were mostly male (62.5%) with active HCV
replication (83%) and had been followed for a median duration of 6.3 years during
which 44.4% achieved a sustained viral response. Higher adiponectinemia levels were
found in cases than in controls (P = 0.01). Levels of the immuno-inflammatory markers
were similar in both groups except sTNFRII >5,000 pg/mL (52% cases versus 24%
controls; P = 0.001). No marker was associated with histological steatosis. Under
multivariate analysis, baseline adiponectin and sTNFRII levels were independently
associated with the occurrence of HCC, alongside previous excessive alcohol intake
and HCV viral load. High baseline circulating adiponectin and sTNFRII levels were
associated with an increased risk of HCC in patients with HCV1 cirrhosis,
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